Latigo Biotherapeutics, Inc. (LTGO)
| Market Cap | 895.68M-28.9% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 60.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 36,250.843 |
| Open | 15.52 |
| Previous Close | 15.52 |
| Day's Range | 14.79 - 15.52 |
| 52-Week Range | 14.79 - 25.93 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 52.25(+250.91%) |
| Earnings Date | n/a |
Latigo Biotherapeutics, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About LTGO
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LTGO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LTGO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LTGO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LTGO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LTGO Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Direct Program Costs Onzotrigine | $8.57M | 60.64% |
| Other clinical and non-clinical programs | $5.56M | 39.36% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LTGO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LTGO from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LTGO
| ETF | Est. Holding Size |
|---|---|
| SCHASchwab U.S. Small-Cap ETF | $1.58M |
| VTIVanguard Morningstar Total Stock Market ETF | $1.22M |
| VXFVanguard Extended Market ETF | $461.23K |
| SCHBSchwab U.S. Broad Market ETF | $194.66K |
| VTWOVanguard Russell 2000 ETF | $174.29K |
| VTWGVanguard Russell 2000 Growth ETF | $17.40K |
Estimated from each fund’s disclosed top holdings × AUM
LTGO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LTGO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score